Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesHematology/OncologyAvMed Adakveo Prior Auth Coverage | OpenPayer
    Ask Trek AI about this page
    CurrentAvMedPolicy Pub. 100-2

    Adakveo (crizanlizumab-tmca) prior authorization

    Customize your policy alerts

    Sign up for AvMed Policy Pub. 100-2 alerts

    Get alerted when Policy Pub. 100-2 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Requirements and clinical criteria for AvMed medical prior authorization of Adakveo (crizanlizumab-tmca) for reducing vaso-occlusive crises in patients with sickle cell disease; applies to providers requesting coverage for the medication.

    Policy Summary
    PayerAvMed
    PolicyAdakveo (crizanlizumab-tmca) prior authorization
    Policy CodePolicy Pub. 100-2
    Change TypeNo material change
    Effective Date
    Next Review Date
    Key ActionPrescriber must complete prior authorization with required clinical documentation, including ICD codes and progress notes documenting VOC events.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    ≥2minimum vaso-occlusive crises
    ≥16minimum age
    5 mg/kgmax dose

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    12 mocontinuation duration
    ≥90 dayshydroxyurea trial

    Coverage Criteria for Adakveo (crizanlizumab-tmca)

    Initial Therapy — Adakveo

    Adakveo is medically necessary for reduction of VOC frequency when ALL of the following are met:

    Initial Authorization

    • VOC frequency: Member has experienced at least 2 vaso-occlusive crises within the preceding 12 months as documented by medical records and ICD diagnosis codes (VOC defined in Part A)>=2 VOCs in 12 months

      Section C

    • Hydroxyurea requirement: Either insufficient response to at least 90 consecutive days of hydroxyurea (defined as >2 VOCs while compliant) OR documented contraindication to hydroxyurea (severe bone marrow depression: leukopenia <2,500/mm3, thrombocytopenia <100,000/mm3, or severe anemia requiring transfusion with labs within 30 days)

      Section C hydroxyurea requirements

    • Specialist involvement and safety criteria: Provider is or has consulted a hematologist/sickle cell specialist; hemoglobin >4.0 g/dL; member is not planning exchange transfusion or on a chronic transfusion program; member is not on chronic anticoagulation other than aspirin; no cancer diagnosis (except non-melanoma skin or in situ cervical) within 5 years; no history of stroke within past 2 years; member is not concomitantly receiving Oxbryta (voxelotor) or Endari (L-glutamine)

      Section B clinical and safety requirements

    Continuation Therapy — Adakveo

    Continuation approved for 12 months when ALL of the following are met:

    Continuation Authorization: Member continues to meet all Section B criteria; documentation demonstrates a decrease in number of VOCs from baseline since starting Adakveo (medical claims, chart notes, and ICD codes from prior approval to current request); and there is absence of unacceptable toxicity (e.g., infusion-related reactions or interference with automated platelet counts)

    Section C reauthorization requirements

    Not Covered / Investigational

    Other uses: Use of Adakveo for indications other than reduction of vaso-occlusive crisis frequency in sickle cell disease is considered investigational

    Section C note

    Use of Adakveo (crizanlizumab-tmca) for any indication other than reduction of vaso-occlusive crisis (VOC) frequency in sickle cell disease is considered investigational.

    Concurrent use of Adakveo (crizanlizumab-tmca) with Oxbryta (voxelotor) or Endari (L-glutamine) will be denied.

    Coding and Clinical Inputs

    Covered HCPCS CodesHCPCSCovered
    J0791Adakveo (crizanlizumab-tmca) Injection
    C9053Adakveo (crizanlizumab-tmca) Injection HCPCS
    VOC Diagnosis CodesICD-10
    282.42Sickle cell crisis code listed
    282.62Sickle cell crisis code listed
    282.64Sickle cell crisis code listed
    282.69Sickle cell crisis code listed
    D57.0Sickle-cell anaemia with crisis
    D57.00Sickle-cell anaemia without crisis
    D57.01Sickle-cell anaemia with acute chest syndrome
    D57.02Sickle-cell anaemia with splenic sequestration
    D57.21HbSC disease with crisis
    D57.211HbSC disease with acute chest syndrome
    1–10 of 21
    1/3
    Vaso-occlusive crises in prior 12 months
    Required number of VOCs>= 2 vaso-occlusive crises in the preceding 12 months
    Documentation requiredICD codes and progress notes with date, outcome, and intervention for each VOC within the last 12 months
    Verification sourcesPharmacy claims and medical record documentation may be used to verify events and treatments
    Hemoglobin — clinical threshold
    Hemoglobin threshold> 4.0 g/dL
    Timing of labHemoglobin must be documented (labs completed within applicable timeframes as requested) prior to initiation

    Provider Requirements and Submission

    Prior Authorization

    Prior authorization required for Adakveo (J0791/C9053)

    Prior authorization is required for Adakveo (crizanlizumab-tmca) Injection (J0791/C9053). The prescribing physician must complete and sign the medical prior authorization/step-edit request and provide all required clinical documentation on the form; incomplete or illegible submissions may delay authorization.

    • Drug Requested: Adakveo (crizanlizumab-tmca) Injection (J0791/C9053)
    • Prescribing physician must sign and clearly print name on the request (preprinted stamps not valid)
    • Complete authorization form including dosing, diagnosis, and required supporting documentation
    Step Therapy

    Hydroxyurea trial (≥90 days) or documented contraindication required

    Member must have had an insufficient response to at least 90 consecutive days of hydroxyurea prior to approval, or have a documented contraindication to hydroxyurea (severe bone marrow depression such as leukopenia <2,500/mm3, thrombocytopenia <100,000/mm3, or severe anemia requiring transfusion). Paid pharmacy claims will be verified.

    Background Information

    Adakveo (crizanlizumab-tmca) is indicated to reduce the frequency of vaso-occlusive crises (VOCs) in patients with sickle cell disease aged 16 years and older. The policy requires documentation of a confirmed sickle cell genotype and at least 2 VOCs in the prior 12 months (as defined by Part A and verified by ICD codes and chart notes). Prior trial of hydroxyurea for at least 90 consecutive days with insufficient response, or a documented contraindication to hydroxyurea, is required. Reauthorization is granted for 12 months when the member continues to meet criteria and shows a documented decrease in VOCs from baseline without unacceptable toxicity. Other uses outside this indication are investigational.

    Definitions and Code Use

    Vaso-occlusive crisis (VOC) — definition
    DefinitionA vaso-occlusive crisis (VOC) is an event prompting a visit or outreach resulting in a VOC diagnosis that requires interventions such as narcotic pain management, non-steroidal anti-inflammatory therapy, hydration, etc.
    DocumentationDate and outcome of the event and the interventions provided must be documented in progress notes
    VerificationICD codes and progress notes and pharmacy claims will be verified within the last 12 months to confirm VOCs
    VOC ICD codes
    ICD codes for VOC verification282.42, 282.62, 282.64, 282.69, D57.0, D57.00, D57.01, D57.02, D57.21, D57.211, D57.212, D57.219, D57.41, D57.411, D57.419, D57.3, D57.412, D57.81, D57.811, D57.812, D57.819
    Use case
    Policy Summary
    PayerAvMed
    PolicyAdakveo (crizanlizumab-tmca) prior authorization
    Policy CodePolicy Pub. 100-2
    Change TypeNo material change
    Effective Date
    Next Review Date
    Key ActionPrescriber must complete prior authorization with required clinical documentation, including ICD codes and progress notes documenting VOC events.
    SourceLink
    On This Page
    Coverage Criteria for Adakveo (crizanlizumab-tmca)Coding and Clinical InputsProvider Requirements and SubmissionBackground InformationDefinitions and Code Use
    Related exclusionsMember must not be planning exchange transfusion or be on a chronic transfusion program at time of initiation
    • Insufficient response defined as >2 VOCs while compliant on hydroxyurea/Droxia during the 90-day trial
    • If contraindication claimed, submit labs within the last 30 days documenting leukopenia, thrombocytopenia, or severe anemia
    • Paid pharmacy claims for hydroxyurea/Droxia within the last 12 months will be verified
    Documentation Required

    Required submission documents and clinical evidence

    Prescriber must sign the prior authorization form and submit member and prescriber information plus supporting clinical documentation, including ICD codes and progress notes documenting VOC events in the last 12 months, relevant lab results, and pharmacy claims to verify prior therapies.

    • Completed and signed medical prior authorization/step-edit request (physician signature required)
    • ICD codes and progress notes documenting VOC events (as defined in Part A) within the prior 12 months
    • Relevant lab results (e.g., hemoglobin, platelet counts) — labs for contraindication claims must be within 30 days
    • Paid pharmacy claims to verify hydroxyurea/Droxia use in the last 12 months
    Denial Risk

    Incomplete or insufficient documentation may delay or deny authorization

    Authorization may be delayed or denied if the information provided is incomplete, incorrect, or illegible, or if supporting documentation (e.g., VOC documentation, labs, pharmacy claims) is missing.

    • Incomplete, incorrect, or illegible submissions can delay authorization
    • Missing documentation of VOC events, labs, or pharmacy claims may result in denial
    Codes represent crisis while in ER/inpatient and are used to verify VOC events
    Documentation requirementProgress notes with date, outcome and intervention must accompany ICD codes for verification